NRAS and melanoma: Overall, the Cobi+Reg combination emerged as a particularly promising combination, with marked in vivo antitumor activity demonstrated against ICB-resistant PDX models encompassing the major molecular melanoma subtypes (i.e., BRAF-, NRAS-, and NF-1–mutant) and after progression on combined ICB in immunocompetent murine melanoma models.